Effect of centrally administered somatostatin on pituitary thyrotropes in male rats

Histochem J. 2000 Sep;32(9):565-9. doi: 10.1023/a:1004158412915.

Abstract

The effects of intracerebroventricularly administered somatostatin (SRIH-14 or -28) on growth and function of pituitary thyrotropes (TSH-cells) were examined in adult male Wistar rats. The animals were implanted with an intracerebroventricular cannula and after a recovery period, administered three 1 microg doses of SRIH-14 or -28 dissolved in 5 microl saline every second day. Controls were treated in the same way with the same volume of saline only. TSH-producing cells were studied using the peroxidase-antiperoxidase immunohistochemical procedure. Blood samples were collected for hormone (TSH) analyses 5 days after the last injection. Both SRIH-treatments significantly decreased (p < 0.05) all morphometric parameters obtained for TSH-cells in comparison with controls. The volume of TSH-cells decreased by 27%, nuclei by 44% and volume density by 33% in animals treated with SRIH-14. In animals treated with SRIH-28, these parameters were also significantly decreased (p < 0.05) (22%, 31%, and 25% respectively) compared to control rats. Serum concentrations of TSH were significantly decreased (p < 0.05) by 15% in SRIH-14- and by 12% in SRIH-28-treated animals in comparison with the controls. These observations suggest that centrally administered SRIH- 14 or -28 is specifically involved in the control of growth and secretory activity of TSH cells.

MeSH terms

  • Animals
  • Injections, Intraventricular
  • Male
  • Organ Size / drug effects
  • Pituitary Gland, Anterior / cytology
  • Pituitary Gland, Anterior / drug effects*
  • Pituitary Gland, Anterior / metabolism
  • Rats
  • Rats, Wistar
  • Somatostatin / administration & dosage
  • Somatostatin / pharmacology*
  • Thyrotropin / metabolism*

Substances

  • Somatostatin
  • Thyrotropin